A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Status:
RECRUITING
Trial end date:
2026-10-31
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).